stoxline Quote Chart Rank Option Currency Glossary
  
Ironwood Pharmaceuticals, Inc. (IRWD)
6.625  -0.205 (-3%)    07-12 12:41
Open: 6.83
High: 6.95
Volume: 346,090
  
Pre. Close: 6.83
Low: 6.6
Market Cap: 1,053(M)
Technical analysis
2024-07-12 12:20:52 PM
Short term     
Mid term     
Targets 6-month :  8.11 1-year :  9.48
Resists First :  6.94 Second :  8.11
Pivot price 6.37
Supports First :  6.03 Second :  5.46
MAs MA(5) :  6.56 MA(20) :  6.22
MA(100) :  7.95 MA(250) :  9.56
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  82.8 D(3) :  78.5
RSI RSI(14): 54.7
52-week High :  15.69 Low :  5.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IRWD ] has closed below upper band by 16.4%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.93 - 6.96 6.96 - 6.98
Low: 6.49 - 6.52 6.52 - 6.55
Close: 6.78 - 6.83 6.83 - 6.87
Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Headline News

Thu, 11 Jul 2024
GSA Capital Partners LLP Acquires New Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat

Thu, 11 Jul 2024
GSA Capital Partners LLP Makes New $1.53 Million Investment in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - American Banking and Market News

Wed, 10 Jul 2024
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Wed, 10 Jul 2024
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Tue, 09 Jul 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by StockNews.com to “Hold” - Defense World

Sun, 07 Jul 2024
Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%? - Yahoo Movies UK

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 159 (M)
Shares Float 140 (M)
Held by Insiders 1.7 (%)
Held by Institutions 110.5 (%)
Shares Short 20,220 (K)
Shares Short P.Month 22,480 (K)
Stock Financials
EPS -6.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.08
Profit Margin -254.5 %
Operating Margin 15.3 %
Return on Assets (ttm) 11.5 %
Return on Equity (ttm) -574.8 %
Qtrly Rev. Growth -28 %
Gross Profit (p.s.) 0
Sales Per Share 2.6
EBITDA (p.s.) 0.93
Qtrly Earnings Growth 0 %
Operating Cash Flow 148 (M)
Levered Free Cash Flow 205 (M)
Stock Valuations
PE Ratio -0.99
PEG Ratio 0.1
Price to Book value -3.21
Price to Sales 2.56
Price to Cash Flow 7.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android